tiprankstipranks
Syndax completes enrollment in AUGMENT-101 trial
PremiumThe FlySyndax completes enrollment in AUGMENT-101 trial
23d ago
Syndax granted Priority Review for NDA for revumenib by FDA
PremiumThe Fly
Syndax granted Priority Review for NDA for revumenib by FDA
24d ago
Syndax price target raised to $34 from $31 at JPMorgan
PremiumThe Fly
Syndax price target raised to $34 from $31 at JPMorgan
1M ago
Syndax Q1 research and development expenses $56M-$62M
PremiumThe FlySyndax Q1 research and development expenses $56M-$62M
2M ago
Syndax reports Q4 EPS ($1.00), consensus (99c)
PremiumThe Fly
Syndax reports Q4 EPS ($1.00), consensus (99c)
2M ago
Incyte says FDA grants priority review for axatilimab
PremiumThe Fly
Incyte says FDA grants priority review for axatilimab
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100